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Abstract
Background: The role of microRNAs (miRNAs) in regulating gene expression is currently an area of intense interest.
Relatively little is known, however, about the role of miRNAs in inflammatory and immunologically-driven disorders.
In a mouse model, we have previously shown that miRNAs are potentially important therapeutic targets in allergic
asthma, because inhibition of miR-126, one of a small subset of miRNAs upregulated in the airway wall, effectively
suppressed Th2-driven airway inflammation and other features of asthma. In the present study, we extended
investigation of the therapeutic potential of miRNA inhibition to our well-established model of chronic asthma.
Methods: Female BALB/c mice were systemically sensitised with ovalbumin (OVA) and chronically challenged with
low mass concentrations of aerosolised OVA for up to 6 weeks. Airway tissue was obtained by blunt dissection and
RNA was isolated for miRNA profiling. On the basis of the results obtained, animals were subsequently treated with
either an antagomir to miR-126 (ant-miR-126) or a scrambled control antagomir once weekly during the 6 weeks
of chronic challenge, and the effects on airway inflammation and remodelling were assessed using established
morphometric techniques.
Results: Compared to naïve mice, there was selective upregulation of a modest number of miRNAs, notably miR-
126, in the airway wall tissue of chronically challenged animals. The relative increase was maximal after 2 weeks of
inhalational challenge and subsequently declined to baseline levels. Compared to treatment with the scrambled
control, ant-miR-126 significantly reduced recruitment of intraepithelial eosinophils, but had no effect on the
chronic inflammatory response, or on changes of airway remodelling.
Conclusions: In this model of chronic asthma, there was an initial increase in expression of a small number of
miRNAs in the airway wall, notably miR-126. However, this later declined to baseline levels, suggesting that
sustained changes in miRNA may not be essential for perpetuation of chronic asthma. Moreover, inhibition of miR-
126 by administration of an antagomir suppressed eosinophil recruitment into the airways but had no effect on
chronic inflammation in the airway wall, or on changes of remodelling, suggesting that multiple miRNAs are likely
to regulate the development of these lesions.
Background
The role of non-coding RNA species in the regulation of
mammalian gene expression is becoming increasingly
apparent [1,2]. Among non-coding RNAs, the microRNAs
(miRNAs) are of particular interest. These are small
non-coding RNAs of approximately 17-24 nucleotides,
each of which is predicted to regulate hundreds of genes
(both coding and non-coding) by post-transcriptional (and
possibly also translational) silencing. There is currently an
intense focus on the role of miRNAs in a variety of human
diseases, ranging from cardiovascular disorders to malig-
nant neoplasms, with active investigation of the potential of
inhibiting miRNAs as a novel approach to treatment [3,4].
T h er o l eo fm i R N A si ni n f l a m m a t o r ya n di m m u n o l o -
gically-driven disorders is slowly being elucidated [5,6].
Studies from our group [7] have identified miRNAs as
potentially important therapeutic targets in allergic
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monary inflammation inducedb yi n t r a n a s a lc h a l l e n g e
with house dust mite (HDM) extract, we demonstrated
selective upregulation of a small subset of miRNAs in
airway tissues. Furthermore, we showed that inhibition
of microRNA-126 (miR-126) by delivery of an antagomir
(a cholesterol-linked single-stranded anti-sense RNA
that selectively binds to this miRNA) effectively sup-
pressed Th2-driven airway inflammation, mucus hyper-
secretion and airway hyper-responsiveness [7].
We therefore sought to extend investigation of the
therapeutic potential of miRNA inhibition in asthma to
a study in our well-established model of chronic asthma
based on long-term low-level challenge with ovalbumin
(OVA) [8,9]. This more closely replicates several key
features of this disease, including acute-on-chronic
inflammation of the airway wall, subepithelial and
epithelial changes of remodelling, airway-specific hyper-
responsiveness, and a spatial distribution of lesions cor-
responding to that observed in human asthma [10]. In
this report, we describe the time course of altered
expression of miRNAs in the airway wall in our model
of chronic asthma and assess the potential of using an
antagomir to inhibit miR-126 (the most highly-upregu-
lated miRNA) as a therapeutic intervention.
Methods
Mice, sensitisation and challenge
The protocols employed for sensitisation and inhala-
tional challenge have previously been described [11].
Briefly, specific pathogen-free female BALB/c mice aged
7-8 weeks (Animal Resources Centre, Perth, Western
Australia) were systemically sensitised by intraperitoneal
injection of 50 μg of alum-precipitated chicken egg
OVA (Grade V, ≥98% pure, Sigma Australia) 21 and 7
days before inhalational challenge, then exposed to aero-
solised OVA in a whole body inhalation exposure cham-
ber (Unifab Corporation, Kalamazoo, MI) [12]. Chronic
low-level challenge involved exposure to ≈3m g / m
3
aerosolised OVA for 30 minutes/day on 3 days/week for
up to 6 weeks. Particle concentration within the cham-
ber was continuously monitored using a DustTrak 8520
instrument (TSI, St Paul, MN). All experimental proce-
dures complied with the requirements of the Animal
Care and Ethics Committee of the University of New
South Wales (reference numbers: 06/119B and 08/09B).
Data were collected from 6 animals per group for
miRNA profiling and 8 animals per group for treatment
with antagomirs. Control groups included naïve mice
a n dm i c et h a tw e r en o ts e n s itised but were challenged
for 6 weeks with aerosolised OVA.
For miRNA profiling, chronic challenge was per-
f o r m e df o r1 ,2 ,4o r6w e e k s .A n i m a l sw e r es a c r i f i c e d
48 hours after the final challenge.
Isolation of Proximal Airway Tissue
Airway tissue was isolated by blunt dissection, using two
pairs of forceps to separate lung parenchyma from the
larger airways and leaving several generations of airway
attached to the trachea [13]. Airway tissue was frozen in
liquid nitrogen until RNA extraction was performed.
Isolation of mRNA and miRNA
For assessment of miRNA, total RNA was isolated from
blunt dissected distal airway tissue of individual animals
using the mirVana miRNA Isolation kit (Ambion). For
assessment of mRNA, RNA was isolated using TriRea-
gent (Sigma) and following DNase treatment (Turbo
DNase, Ambion), samples were reverse transcribed into
cDNA using Superscript III (Invitrogen).
miRNA microarray
miRNAs were enriched with the Ambion flashPAGE
system. The Ambion 1564V1 probeset was printed on
microarray epoxy slides by the Australian Genome
Research Facility, Parkville, Australia. miRNA was polya-
denylated and labelled with Cy3 using the mirVana
miRNA labelling kit and arrays were hybridised and
washed as described by Ambion. Slides were scanned
using a GenePix4000B (Molecular Devices) and GenePix
6.0 software was used to quantify raw signal intensities.
Analysis of microarray data was conducted using Gene-
spring GX 11 software (Agilent). Percentile shift normal-
isation (75
th percentile) was performed with subsequent
fold change calculations conducted against mean nor-
malised naïve expression levels.
Quantitative RT-PCR
qRT-PCR for miRNA was performed using TaqMan
Gene Expression Assays for the respective miRNA
(Applied Biosystems). miRNA expression was normal-
ised to sno202 RNA. qRT-PCR for mRNA expression
used primers that were custom-designed in house. Reac-
tions were performed using an ABI Prism 7700
Sequence Detector (Applied Biosystems). Amplified pro-
ducts were detected using SYBR green and expression
was normalised to hypoxanthine-guanine phosphoribosyl
transferase.
Antagomirs
Target miRNA sequences were downloaded from miR-
Base, Faculty of Life Sciences, University of Manchester,
UK (http://www.mirbase.org/). We ordered antagomirs
from Dharmacon. The scrambled antagomir was nonspe-
cific RNA VIII, blasted against the mouse genome. The
sequence of ant-miR-126 was: 5’ mG.*.mC.*.mA.mU.mU.
mA.mU.mU.mA.mC.mU.mC.mA.mC.mG.mG.mU.mA.*.
mC.*.mG.*.mA.*. 3’ -Chl, where ‘’m’’ were 2’-OMe modi-
fied phosphoramidites, ‘’*’’ were phosphorothioate
Collison et al. BMC Pulmonary Medicine 2011, 11:29
http://www.biomedcentral.com/1471-2466/11/29
Page 2 of 6linkages, and ‘’-Chl’’ was hydroxyprolinol-linked choles-
terol. For antagomir therapy, chronic challenge was per-
formed as above for 6 weeks. Mice received either the
antagomir to miR-126 (ant-miR-126) or the control
antagomir based on the scrambled sequence (ant-
scrambled) once per week intranasally. For both antago-
mirs, the dose was 50 μgi n5 0μL sterile saline (25 μL
per nare) as previously described [7].
Assessment of airway inflammation and remodelling
In the antagomir and control-treated mice, asthmatic
inflammation and airway wall remodelling were quanti-
fied in longitudinally oriented sections of formalin-fixed,
paraffin-embedded tracheas, or horizontally oriented
sections from the mid-zone of the single lobed left lung,
as previously described [8]. Assessment included num-
bers of intraepithelial eosinophils and of chronic inflam-
matory cells in the lamina propria of the airway, extent
of subepithelial fibrosis and grading of mucous cell
change. The validity and reliability of the morphometric
techniques we employed have been established in pre-
vious reports [8,14].
Immunostaining
Expression of eotaxin in the airway epithelium was
demonstrated using a goat polyclonal antibody to a 19-
amino acid peptide corresponding to an epitope at the car-
boxy terminus of mouse eotaxin (Santa Cruz Biotechnol-
ogy, Santa Cruz, California) (sc-6182). Immunoperoxidase
staining of formalin-fixed, paraffin-embedded sections was
performed following antigen retrieval in 0.01M citrate buf-
fer (pH 6.0), as previously described [15]. Intensity of
immunoreactivity was semi-quantitatively scored as grade
0 = no staining, grade 1 = weak staining, grade 2 = moder-
ate staining and grade 3 = strong staining.
Statistical analysis
Results are presented as mean ± SEM, or as medians
(interquartile range) for grading. Differences between
groups were assessed using a one-way ANOVA or Krus-
kal-Wallis test, followed by a Newman-Keuls or Dunn’s
post test as appropriate. The software package Graph-
Pad Prism 5.01 (GraphPad Software, San Diego, CA)
was used for data analysis and preparation of graphs.
Results and Discussion
Altered expression of miRNAs in the airway wall in
chronic asthma
Compared to naïve mice, there was selective upregula-
tion of a modest number of miRNAs in the airway wall
tissue of sensitised, chronically challenged animals. Only
11 miRNAs exhibited a 2-fold or greater increase: these
were miR-126, -197, -341, -145, -30c, -23b, -199a, -29a,
-129-3p, -16 and -495 (Table 1). The complete dataset
is deposited at ArrayExpress (http://www.ebi.ac.uk/
arrayexpress) (accession number E-MEXP-3118).
Notably, levels of expression of miR-126 were
increased to a much greater extent than those of any
other upregulated miRNA, and this was confirmed by
qRT-PCR (Figure 1). There was clear evidence of regula-
tion of changes in miRNA expression over time: the
relative increase was maximal after 2 weeks of inhala-
tional challenge and subsequently declined, so that
except for miR-126 all had returned to baseline levels by
6 weeks (Table 1).
In the control group of animals that were not sensi-
tised but were challenged for 6 weeks with aerosolised
Table 1 Fold change in expression of miRNAs in airway
wall tissues during chronic challenge
Week 1 Week 2 Week 4 Week 6
miR-126 3.11 7.93 4.56 2.33
miR-197 1.41 2.54 1.55 1.25
miR-341 1.23 2.37 1.62 1.39
miR-145 1.92 2.36 1.62 1.04
miR-30c 1.63 2.26 1.55 1.18
miR-23b 1.2 2.12 1.43 1.03
miR-199a 1.19 2.11 1.38 1.19
miR-29a 1.09 2.06 1.42 1.09
miR-129-3p 1.56 2.04 1.5 1.31
miR-16 1.2 2.03 1.4 1.03
miR-495 1.27 2.02 1.36 1.14
Changes in relative expression of individual miRNAs relative to levels in naïve
animals, as assessed by microarray profiling. All miRNAs with >2-fold
upregulation at 2 weeks of challenge are listed. Downregulation at other time
points is shown in italics.
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Figure 1 Relative expression of miR-126.q R T - P C Rc o n f i r m a t i o n
of upregulation of miR-126 in airway wall tissue of animals
following chronic challenge. Significant differences compared to
naïve controls are shown as * (p < 0.05), *** (p < 0.001); significant
differences compared to mice challenged for 2 weeks are shown as
# (p < 0.05), ### (p < 0.001).
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upregulated by 2-fold or greater. Of these, miR-126 was
again the most highly upregulated, with a 5-fold increase
compared to naïve mice. This is of interest because we
have previously shown that although these animals are
not systemically sensitised, there is low-level sensitisa-
tion via the respiratory tract as a consequence of the
chronic challenge, leading to a specific humoral immune
response [16].
Some of the current findings with respect to altered
expression of miRNA in the airway wall are congru-
ent with our previous report [7] which similarly
detected upregulation of a limited number of miRNAs
following induction of allergic inflammation [7]. In
that previous study, which was based on a short-term
model of HDM-induced asthmatic airway inflamma-
tion, miR-126 was the most highly upregulated
miRNA in the airway wall. In the present study, we
have confirmed that miR-126 is potentially a very
important miRNA in asthmatic inflammation, because
it was also the most highly upregulated miRNA in the
chronic OVA challenge model. Interestingly, in the
previous study miR-16 was also upregulated in the
HDM model and this was again observed in the
chronic OVA model. However, there were some
important differences in the model of chronic asthma,
notably the absence of demonstrable upregulation of
miR-21, and evidence of upregulation of 10 additional
miRNAs.
Because we assessed expression of miRNA in airway
wall tissues, we do not have information about changes
in specific cell types. Airway wall tissues include struc-
tural cells (such as airway epithelium, fibroblasts,
smooth muscle, cartilage, vascular tissues) and recruited
inflammatory cells. Importantly, unlike in short-term
models of allergic inflammation of the airways, in our
chronic challenge model there is a substantial change in
the inflammatory cellular profile in the airway wall over
time. Notably there is progressive accumulation of cells
associated with chronic inflammation, especially CD3
+
T-lymphocytes and plasma cells [13,16]. Whether cell-
specific changes account for the different profile of
expression of miRNA in the chronic challenge model is
at present unclear.
Whereas in the HDM model we assessed changes in
expression of miRNA following two challenges 10 days
apart, in the present study we were able to examine the
time course of changes in expression of upregulated
miRNAs. Remarkably, this revealed that upregulation
was not sustained with continuing challenge, which
could imply that expression of these miRNAs plays a
more important role in the initiation rather than the
perpetuation of asthmatic lesions.
Effects of treatment with antagomir to miR-126 on
changes of chronic asthma
Animals that were treated with the scrambled control
antagomir developed airway wall changes that were
indistinguishable from those observed in the chronic
challenge model without any treatment [8], including
recruitment of significant numbers of intraepithelial
eosinophils, accumulation of chronic inflammatory cells
in the lamina propria, subepithelial fibrosis and wide-
spread goblet cell hyperplasia/metaplasia (Figure 2).
Long-term administration of ant-miR-126 significantly
reduced the numbers of intraepithelial eosinophils in
the conducting airways (Figure 2A). However, treatment
with ant-miR-126 had no effect on the chronic inflam-
matory response (Figure 2B). Similarly, changes of
remodelling were essentially identical to those in mice
treated with ant-scrambled (Figure 2C, D).
To verify that delivery of ant-miR-126 was effective,
we assessed the expression of TOM1 (target of Myb1)
which is a negative regulator of IL-1b and TNF-a
-induced signalling pathways. TOM1 has been defined
as a target of miR-126 and is downregulated by it [17].
While there was no change in the expression of TOM1
in animals treated with ant-scrambled when compared
to naïve mice, TOM1 was markedly and significantly
upregulated in animals treated with ant-miR-126
(Figure 3). Whether TOM1 has any function in this
model is unknown; however, this finding confirmed that
ant-miR-126 was biologically active in the airway wall of
these animals. Because samples from the antagomir-
treated animals were processed for assessment of
expression of mRNA, not miRNA, we were unable to
directly confirm the effects of treatment with antagomirs
on the levels of miR-126.
We have previously shown that accumulation of
intraepithelial eosinophils is related to upregulation of
expression of eotaxin in the airway epithelium in
response to inhalational challenge [15]. To investigate
whether the mechanism of the reduction in numbers of
eosinophils in antagomir-treated mice was related to
inhibition of expression of eotaxin, we performed immu-
nostaining on sections of tracheas. As expected, there
was increased immunoreactivity for eotaxin in the
epithelium of animals treated with ant-scrambled (med-
ian grade 2.0, range 1-3). There was a reduction in ani-
mals treated with ant-miR-126 (median grade 1.0, range
0-2), although this difference was not statistically signifi-
cant. Whether ant-miR-126 had any other cell-specific
effects in this model is unknown.
In our previous study in an HDM-induced model of
asthmatic airway inflammation, we showed that selective
inhibition of miR-126 using a specific antagomir inhib-
ited eosinophil recruitment and AHR [7]. The evidence
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suppressing eosinophil recruitment into the airways in
t h em o d e lo fc h r o n i ca s t h m ai se n c o u r a g i n gi nt e r m so f
the potential of antagomir therapy. However, in the
short-term HDM model it was not possible to assess the
effects of ant-miR-126 on chronic inflammation in the
airway wall, or on the development of airway remodel-
ling. Unfortunately, we found that treatment with ant-
miR-126 did not inhibit the progression of these lesions.
While the frequency of delivery of antagomirs was lower
in the present study (once weekly rather than alternate
days) it is not altogether surprising that targeting a single
miRNA would not suppress all of the changes in a com-
plex disorder such as chronic asthma. We have pre-
viously demonstrated that in many respects, the lesions
of asthma are expressed differently in our chronic chal-
lenge model as compared to a short-term model of aller-
gic pulmonary inflammation [9,18]. Thus our data
suggest that ant-miR-126 alone has limited therapeutic
potential in asthma. Nevertheless, they emphasise the
importance of elucidating the role of other regulatory
miRNAs in asthmatic airway inflammation, such as those
we have identified in this study, which might allow the
development of appropriate combination therapy.
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Figure 2 Morphometric assessment of the effects of antagomir treatment. Quantification of (A) profile density of intraepithelial eosinophils
(B) profile density of chronic inflammatory cells in the lamina propria (C) thickness of subepithelial collagenisation (all assessed in the trachea)
and (D) grade of mucous cell change (assessed in intrapulmonary airways) after 6 weeks of chronic challenge and antagomir treatment. Values
are expressed as mean ± SEM (A-C) or median ± interquartile range (D); 8 animals were assessed per group. Significant differences compared to
naïve controls are shown as * (p < 0.05), ** (p < 0.01), *** (p < 0.001); significant difference compared to mice treated with ant-scrambled is
shown as # (p < 0.05).
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Figure 3 Relative expression of mRNA for TOM1.q R T - P C R
confirmation of upregulation of TOM1 in airway wall tissue of
animals that received 6 weeks of chronic challenge and treatment
with ant-miR-126. Significant difference compared to naïve controls
is shown as ** (p < 0.01), compared to mice treated with ant-
scrambled is shown as ## (p < 0.01).
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In this model of chronic asthma, inhalational challenge
with OVA initially increased the expression of a small
number of miRNAs in the airway wall, notably miR-126.
By 6 weeks of challenge, however, this enhanced expres-
sion has largely declined to baseline levels, suggesting
that sustained changes in miRNA may not be essential
for perpetuation of chronic asthma. Inhibition of miR-
126 by long-term administration of an antagomir sup-
pressed eosinophil recruitment into the airways. How-
ever, this treatment had no effect on chronic
inflammation in the airway wall, or on changes of remo-
delling, reinforcing the complexity of chronic asthma
and the likelihood that multiple miRNAs regulate the
development of these lesions.
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